KV Pharmaceutical Company Reports Fiscal 2009 First Quart...(bsorption. Repliva 21/7(R) currently ...),Health

Repliva 21/7(R) currently holds a 7.6% new prescription share, up from 5.9% in the first quarter of the previous fiscal year, representing the highest new prescription share of all branded oral iron products in the United States.

Advanced Prescription Nutritionals

Net revenues for all of the products that comprise Ther-Rx's advanced prescription nutritional line were $27.5 million, comparable with the first quarter of fiscal 2008.

-- Ther-Rx maintained its market leading position as the most prescribed prenatal vitamin franchise in the United States with a 43.9% share of the branded prescription prenatal market.

-- Net sales from our advanced prescription nutritional product line were comparable with the prior year quarter. The year-over-year comparison of sales of this product line was negatively impacted by $3.0 million in lower volume due to larger-than-normal customer purchases made in the first quarter last year due to anticipated price increases.

-- The PrimaCare(R) line of products maintained a 47.1% share of the Omega-3 (Essential Fatty Acid) segment of the branded prescription nutritional marketplace.

Gestiva(TM)

In January 2008, KV acquired an important asset that we anticipate will be added to the Ther-Rx women's healthcare line of products. The Company entered into a definitive product purchase agreement in fiscal 2008 that gives KV full U.S. and worldwide rights to Gestiva(TM) (17a-hydroxyprogestorone caproate) upon FDA approval of the pending New Drug Application for this product. The pending NDA seeks approval of Gestiva(TM), which has been granted an Orphan Drug Designation by the FDA, for use in the prevention of preterm birth for women with a history of at least one spontaneous preterm delivery (i.e., less than 37 weeks) who are pregnant with a single fetus. A PDUFA date by which FDA is expected to make a decision on the Gestiva(TM) NDA is October 24, 2008. We believe that Gestiva(T
'/>"/>